Efficacy and safety of Amomum villosum extracts in obese adults: A randomized, double-blind, placebo-controlled trial

被引:1
|
作者
Lee, Jung-Han [1 ]
Kim, Ha-Rim [2 ,3 ]
Antonisamy, Paulrayer [2 ,3 ]
Kim, Ye-Seul [2 ,3 ]
Ryu, Do-Gon [2 ]
Lee, Guemsan [4 ]
Kwon, Kang-Beom [2 ,3 ,5 ,6 ]
机构
[1] Wonkwang Univ, Coll Korean Med, Dept Korean Med Rehabil, Iksan, Jeonbuk, South Korea
[2] Wonkwang Univ, Coll Korean Med, Dept Physiol, Iksan, Jeonbuk, South Korea
[3] Ilwonbio Co Ltd, Iksan, Jeonbuk, South Korea
[4] Wonkwang Univ, Coll Korean Med, Dept Herbol, Iksan, Jeonbuk, South Korea
[5] Ilwonbio Co Ltd, 460 Iksandaero, Iksan 54538, Jeonbuk, South Korea
[6] Wonkwang Univ, Dept Physiol, Coll Korean Med, 460 Iksandaero, Iksan 54538, South Korea
关键词
Amomum villosum; Body weight; Obesity; Visceral adipose tissue; Randomized controlled trial; BODY-WEIGHT; WAIST CIRCUMFERENCE; FAT ACCUMULATION; OVERWEIGHT; INDIVIDUALS; LEPTIN;
D O I
10.1016/j.jksus.2023.102580
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Objective: This study aimed to assess how well Amomum villosum water extract (AVE) assisted over-weight to moderately obese people in losing weight. Methods: Eighty participants were chosen at random for the AVE group or the placebo group for this experiment. Subjects were given two tablets of the test substance after their two consistent meals daily for 12 weeks. At the starting and completion of the experiment, measurements of body mass index (BMI), body weight, percent body fat, body fat mass, visceral adipose tissue (VAT), lean body mass, subcuta-neous adipose tissue (SAT), percent VAT (%), and percent SAT (%) were taken. Before and after the study, blood samples were obtained for safety laboratory parameters. Results: After taking the products for 12 weeks, the AVE group lost considerably more weight than the placebo group (-2.04 +/- 3.04 kg vs-0.30 +/- 2.88 kg, respectively; P < 0.014). Additionally, the AVE group showed reduction in body fat mass of-1393.63 +/- 2268.80 g as compared to the placebo group's reduc-tion of 51.67 +/- 2111.05 g (P < 0.006). In comparison to the placebo group, VAT and SAT weight signifi-cantly lowered in the AVE group. There were no negative effects associated with AVE consumption. Before and after AVE administration, 31 of 38 participants (81.6 %) lost weight. Similarly, 26 of 38 mem-bers (68.4 %) lost weight and body fat mass before and after AVE administration. Conclusions: These results suggest that AVE might be a reliable and secure weight regulation. WKUIOMH-IRB-2020-01 is the registration number for this trial. (c) 2023 The Authors. Published by Elsevier B.V. on behalf of King Saud University. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
引用
收藏
页数:7
相关论文
共 50 条
  • [31] Efficacy and safety of Obex® in overweight and obese subjects: a randomised, double-blind, placebo-controlled clinical trial
    Eduardo Cabrera-Rode
    Ileana Cubas-Dueñas
    Janet Rodríguez Acosta
    Jeddú Cruz Hernández
    Ana Ibis Conesa González
    Teresa M. González Calero
    Yuri Arnold Domínguez
    José Hernández Rodríguez
    Antonio D. Reyes Rodríguez
    Aimee Álvarez Álvarez
    Ragmila Echevarría Valdés
    Liudmila Jorge Espinosa
    Onelia Torres Belent
    Zoila Bell Benavides
    Elizabeth Senra Estévez
    Yanet Abreu Rodríguez
    Juana del Valle Rodríguez
    Silvia Marín Juliá
    BMC Complementary Medicine and Therapies, 23
  • [32] Double-blind randomized placebo-controlled trial of sibutramine
    Bray, GA
    Ryan, DH
    Gordon, D
    Heidingsfelder, S
    Cerise, F
    Wilson, K
    OBESITY RESEARCH, 1996, 4 (03): : 263 - 270
  • [33] Efficacy of Enalapril in Migraine Prophylaxis: A Randomized, Double-blind, Placebo-controlled Trial
    Sonbolestan, Seyed Ali
    Heshmat, Kiyan
    Javanmard, Shaghayegh Haghjooy
    Saadatnia, Mohammad
    INTERNATIONAL JOURNAL OF PREVENTIVE MEDICINE, 2013, 4 (01) : 72 - 77
  • [34] The efficacy of azithromycin in pityriasis rosea: A randomized, double-blind, placebo-controlled trial
    Pandhi, Deepika
    Singal, Archana
    Verma, Prashant
    Sharma, Reena
    INDIAN JOURNAL OF DERMATOLOGY VENEREOLOGY & LEPROLOGY, 2014, 80 (01): : 36 - 40
  • [35] Vaccine for cocaine dependence: A randomized double-blind placebo-controlled efficacy trial
    Kosten, Thomas R.
    Domingo, Coreen B.
    Shorter, Daryl
    Orson, Frank
    Green, Charles
    Somoza, Eugene
    Sekerka, Rachelle
    Levin, Frances R.
    Mariani, John J.
    Stitzer, Maxine
    Tompkins, D. Andrew
    Rotrosen, John
    Thakkar, Vatsal
    Smoak, Benjamin
    Kampman, Kyle
    DRUG AND ALCOHOL DEPENDENCE, 2014, 140 : 42 - 47
  • [36] Efficacy and safety of diacerein in osteoarthritis of the knee - A double-blind, placebo-controlled trial
    Pelletier, JP
    Yaron, M
    Haraoui, B
    Cohen, P
    Nahir, MA
    Choquette, D
    Wigler, I
    Rosner, IA
    Beaulieu, AD
    ARTHRITIS AND RHEUMATISM, 2000, 43 (10): : 2339 - 2348
  • [37] Efficacy of Hydroxychloroquine in Hand Osteoarthritis: A Randomized, Double-Blind, Placebo-Controlled Trial
    Lee, Weiching
    Ruijgrok, Liesbeth
    Boxma-de Klerk, Bianca
    Kok, Marc R.
    Kloppenburg, Margreet
    Gerards, Andreas
    Huisman, Margriet
    Hazes, Mieke
    de Sonnaville, Peter
    Grillet, Bart
    Weel, Angelique
    Basoski, Natalja
    ARTHRITIS CARE & RESEARCH, 2018, 70 (09) : 1320 - 1325
  • [38] Efficacy and tolerability of almotriptan in adolescents: A randomized, double-blind, placebo-controlled trial
    Linder, Steven L.
    Mathew, Ninan T.
    Cady, Roger K.
    Finlayson, Gary
    Ishkanian, Gary
    Lewis, Donald W.
    HEADACHE, 2008, 48 (09): : 1326 - 1336
  • [39] A DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF NALTREXONE IN OBESE MALES
    MITCHELL, JE
    MORLEY, JE
    HATSUKAMI, D
    APPETITE, 1985, 6 (02) : 212 - 212
  • [40] The Bexagliflozin Efficacy and Safety Trial (BEST): A Randomized, Double-Blind, Placebo-Controlled, Phase IIII, Clinical Trial
    McMurray, John J. V.
    Freeman, Mason W.
    Massaro, Joe
    Solomon, Scott
    Lock, Paul
    Riddle, Matthew C.
    Halvorsen, Yuan-Di C.
    DIABETES, 2020, 69